Jul. 15 at 6:18 AM
$MLTX
Why stress over daily price swings on
$MLTX when you are holding a generational biotech winner? The short-term noise is irrelevant compared to the clinical reality.
As of July 15, 2026, the science has settled any doubts. The final Week 52 Phase 3 VELA-1 & VELA-2 results (released June 21, 2026) are stellar: 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100. Remarkably, 26.0% reached IHS4-100 response, indicating complete inflammatory remission with zero abscesses, nodules, or draining tunnels.
Sonelokimab's tri-specific Nanobody design (blocking IL-17A/A, IL-17A/F, IL-17F/F) has an ultra-small molecular size that yields deep tissue penetration classic mAbs can't match, outperforming competitors by ~10% in long-term efficacy.
With FDA alignment secured and the BLA submission on track for late September 2026, stop checking the ticker.
